Binding of a tritiated inverse agonist to cannabinoid CB1 receptors is increased in patients with schizophrenia

Kimberly J. Jenko; Jussi Hirvonen; Ioline D. Henter; Kacey B. Anderson; Sami S. Zoghbi; Thomas Hyde; Amy Deep-Soboslay; Robert B. Innis; Joel E. Kleinman

doi:10.1016/j.schres.2012.07.021

Binding of a tritiated inverse agonist to cannabinoid CB₁ receptors is increased in patients with schizophrenia

Kimberly J. Jenko, Jussi Hirvonen, Ioline D. Henter, Kacey B. Anderson, Sami S. Zoghbi, Thomas Hyde, Amy Deep-Soboslay, Robert B. Innis, Joel E. Kleinman

Research output: Contribution to journal › Article › peer-review

36 Scopus citations

Abstract

This study sought to determine whether cannabinoid-1 (CB₁) receptor binding was altered in the postmortem dorsolateral prefrontal cortex (DLPFC) of individuals with schizophrenia (schizophrenia; n=47) compared to controls (n=43). The CB₁ receptor inverse agonist radioligand [³H]MePPEP was used to measure specific binding to CB₁ receptors. The specific binding of [³H]MePPEP to CB₁ receptors was 20% higher in patients with schizophrenia than in controls. Power analyses suggested that 53 subjects per group would be needed to detect a similar difference in vivo with positron emission tomography (PET) and the structurally related inverse agonist radioligand [¹⁸F]FMPEP-d₂ (80% statistical power, p<0.05).

Original language	English (US)
Pages (from-to)	185-188
Number of pages	4
Journal	Schizophrenia Research
Volume	141
Issue number	2-3
DOIs	https://doi.org/10.1016/j.schres.2012.07.021
State	Published - Nov 2012
Externally published	Yes

Keywords

CB
Cannabinoid
Dorsolateral prefrontal cortex
Schizophrenia
[H]MePPEP

ASJC Scopus subject areas

Psychiatry and Mental health
Biological Psychiatry

Access to Document

10.1016/j.schres.2012.07.021

Cite this

@article{e9c448acb0c34a439a12c99a975c0404,

title = "Binding of a tritiated inverse agonist to cannabinoid CB1 receptors is increased in patients with schizophrenia",

abstract = "This study sought to determine whether cannabinoid-1 (CB1) receptor binding was altered in the postmortem dorsolateral prefrontal cortex (DLPFC) of individuals with schizophrenia (schizophrenia; n=47) compared to controls (n=43). The CB1 receptor inverse agonist radioligand [3H]MePPEP was used to measure specific binding to CB1 receptors. The specific binding of [3H]MePPEP to CB1 receptors was 20% higher in patients with schizophrenia than in controls. Power analyses suggested that 53 subjects per group would be needed to detect a similar difference in vivo with positron emission tomography (PET) and the structurally related inverse agonist radioligand [18F]FMPEP-d2 (80% statistical power, p<0.05).",

keywords = "CB, Cannabinoid, Dorsolateral prefrontal cortex, Schizophrenia, [H]MePPEP",

author = "Jenko, {Kimberly J.} and Jussi Hirvonen and Henter, {Ioline D.} and Anderson, {Kacey B.} and Zoghbi, {Sami S.} and Thomas Hyde and Amy Deep-Soboslay and Innis, {Robert B.} and Kleinman, {Joel E.}",

note = "Funding Information: This study was supported in part by the Intramural Research Program of the National Institute of Mental Health, National Institutes of Health (IRP‐NIMH‐NIH) . The NIMH had no further role in study design; in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the paper for publication. ",

year = "2012",

month = nov,

doi = "10.1016/j.schres.2012.07.021",

language = "English (US)",

volume = "141",

pages = "185--188",

journal = "Schizophrenia Research",

issn = "0920-9964",

publisher = "Elsevier",

number = "2-3",

}

TY - JOUR

T1 - Binding of a tritiated inverse agonist to cannabinoid CB1 receptors is increased in patients with schizophrenia

AU - Jenko, Kimberly J.

AU - Hirvonen, Jussi

AU - Henter, Ioline D.

AU - Anderson, Kacey B.

AU - Zoghbi, Sami S.

AU - Hyde, Thomas

AU - Deep-Soboslay, Amy

AU - Innis, Robert B.

AU - Kleinman, Joel E.

N1 - Funding Information: This study was supported in part by the Intramural Research Program of the National Institute of Mental Health, National Institutes of Health (IRP‐NIMH‐NIH) . The NIMH had no further role in study design; in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the paper for publication.

PY - 2012/11

Y1 - 2012/11

N2 - This study sought to determine whether cannabinoid-1 (CB1) receptor binding was altered in the postmortem dorsolateral prefrontal cortex (DLPFC) of individuals with schizophrenia (schizophrenia; n=47) compared to controls (n=43). The CB1 receptor inverse agonist radioligand [3H]MePPEP was used to measure specific binding to CB1 receptors. The specific binding of [3H]MePPEP to CB1 receptors was 20% higher in patients with schizophrenia than in controls. Power analyses suggested that 53 subjects per group would be needed to detect a similar difference in vivo with positron emission tomography (PET) and the structurally related inverse agonist radioligand [18F]FMPEP-d2 (80% statistical power, p<0.05).

AB - This study sought to determine whether cannabinoid-1 (CB1) receptor binding was altered in the postmortem dorsolateral prefrontal cortex (DLPFC) of individuals with schizophrenia (schizophrenia; n=47) compared to controls (n=43). The CB1 receptor inverse agonist radioligand [3H]MePPEP was used to measure specific binding to CB1 receptors. The specific binding of [3H]MePPEP to CB1 receptors was 20% higher in patients with schizophrenia than in controls. Power analyses suggested that 53 subjects per group would be needed to detect a similar difference in vivo with positron emission tomography (PET) and the structurally related inverse agonist radioligand [18F]FMPEP-d2 (80% statistical power, p<0.05).

KW - CB

KW - Cannabinoid

KW - Dorsolateral prefrontal cortex

KW - Schizophrenia

KW - [H]MePPEP

UR - http://www.scopus.com/inward/record.url?scp=84866934658&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866934658&partnerID=8YFLogxK

U2 - 10.1016/j.schres.2012.07.021

DO - 10.1016/j.schres.2012.07.021

M3 - Article

C2 - 22910406

AN - SCOPUS:84866934658

SN - 0920-9964

VL - 141

SP - 185

EP - 188

JO - Schizophrenia Research

JF - Schizophrenia Research

IS - 2-3

ER -